Featured Research

from universities, journals, and other organizations

Yale Cancer Center Researchers Find Ways To Switch Off Cancer Cells' Protection

Date:
December 9, 1999
Source:
Yale University
Summary:
Yale Cancer Center researchers have identified two mechanisms to disable the Survivin gene, identified in earlier studies as an inhibitor to apoptosis, the programmed death of cancer cells. The research appears in the December issue of the Journal Nature Cell Biology.

(NEW HAVEN) -- Yale Cancer Center researchers have identified two mechanisms to disable the Survivin gene, identified in earlier studies as an inhibitor to apoptosis, the programmed death of cancer cells. The research appears in the December issue of the Journal Nature Cell Biology.

Scientists, led by Dario C. Altieri, M.D., professor of pathology at the Yale University School of Medicine, used two different classes of molecular antagonists to interfere with the function of Survivin and eliminate its protective properties. The first is antisense, a DNA molecule that prevents the transfer of genetic code information from the Survivin gene. The second antagonist is a mutant form of the Survivin itself, but with a function completely unlike that of the original.

According to the in-vitro study using cervical carcinoma cells, both approaches produced one of two different responses. In some cases, the cancer cells died spontaneously. Those that didn't die immediately exhibited a profound defect in cell division, causing them to become unstable and die eventually. "The two independent strategies were comparable in terms of efficacy," said Altieri. "The response to each was of the same frequency and magnitude; the cancer cell is very sensitive to change."

An earlier study led by Altieri identified Survivin as a target in that it acts as a switch for cancer cells, allowing them to stay alive and continue normal cell division. "We now have another piece of the picture of how Survivin functions, and we are hopeful that this new information about potential antagonists can ultimately be used therapeutically. Survivin plays a central role in the cancer cell cycle, and its antagonists may be integrated into first-line treatments. It's one more molecular approach that, when combined with chemotherapy, may prove to increase its effectiveness, Altieri said."

"The distribution of expression of Survivin in human cancers but not in normal adult human cells, and a pattern of expression in cancer cells suggests that interruption of its function may well be one of the prime targets of this decade," said Vincent T. DeVita, Jr., M.D., director of the Yale Cancer Center.

Initial results of preclinical studies at Yale using another strain of mutant Survivin in a melanoma model in mice have shown promise, according to Altieri. And a study using antisense in that same melanoma model is about to get underway.

Other collaborators on the study include Janet Plescia and Annette Rothermel of the Yale University School of Medicine, as well as investigators from the San Raffaele Scientific Institute in Milan, Italy and Isis Pharmaceuticals in Carlsbad, California.

The Yale Cancer Center is one of a select network of comprehensive cancer centers in the country designated by the National Cancer Institute and the only one in Southern New England. Bringing together the resources of Yale-New Haven Hospital and the Yale University School of Medicine, its mission encompasses patient care, research, cancer prevention and control, community outreach and education.


Story Source:

The above story is based on materials provided by Yale University. Note: Materials may be edited for content and length.


Cite This Page:

Yale University. "Yale Cancer Center Researchers Find Ways To Switch Off Cancer Cells' Protection." ScienceDaily. ScienceDaily, 9 December 1999. <www.sciencedaily.com/releases/1999/12/991209045251.htm>.
Yale University. (1999, December 9). Yale Cancer Center Researchers Find Ways To Switch Off Cancer Cells' Protection. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/1999/12/991209045251.htm
Yale University. "Yale Cancer Center Researchers Find Ways To Switch Off Cancer Cells' Protection." ScienceDaily. www.sciencedaily.com/releases/1999/12/991209045251.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins